# fac-10 — Dengue virus serotypes  (raw panel responses + judge-синтез)
**Prompt:** How many confirmed serotypes does the dengue virus have? List them by name. Why does secondary infection with a *different* serotype cause more severe disease than the first infection?

> ВНИМАНИЕ: responses релеятся caller'ом (qwen3-235b), не verbatim — атрибуция модели местами заменена ролью ('Panel Model A'); текст ответа реальный.


======================================================================
## C1_west_closed  (panel=[gpt-5.2, gemini-3.1-pro-preview, grok-4.3] | judge=gpt-5.2)

### JUDGE-СИНТЕЗ (что судья извлёк):
**consensus:**   - Dengue virus has 4 confirmed serotypes: DENV-1, DENV-2, DENV-3, DENV-4 (supported by current public-health references such as CDC and PAHO).
  - Secondary infection with a different (heterologous) serotype is associated with higher risk of severe dengue, largely explained by antibody-dependent enhancement (ADE): pre-existing cross-reactive but insufficiently neutralizing antibodies can increase infection of Fc-receptor–bearing immune cells, raising viremia and inflammatory/vascular-leak pathology.
**contradictions:** 
  - {"topic": "Whether heterologous secondary infection is inherently/typically more severe vs a probabilistic risk factor (severe dengue can also occur in primary infection)", "stances": [{"model": "openai/gpt-5.2", "stance": "Frames as a main reason a second infection with a different serotype can be more severe (risk-oriented language, but still implies a general mechanism explanation)."}, {"model": "google/gemini-3.1-pro-preview", "stance": "Says a secondary infection with a different serotype typically causes more severe disease (stronger implication of typicality)."}, {"model": "x-ai/grok-4.3", "stance": "Explicitly notes risk is higher on second infection but severe dengue can occur on first or later infections too."}, {"model": "evidence", "stance": "Epidemiology and clinical guidance describe heterologous secondary infection as an important risk factor, not a necessary or sufficient cause; severe dengue also occurs in some primary infections (and in infants with waning maternal antibodies)."}]}
**unique_insights:** 
  - {"model": "x-ai/grok-4.3", "insight": "Makes the important nuance explicit that although heterologous secondary infection is a major risk factor, severe dengue is not exclusive to second infections (it can occur in primary or later infections depending on context)."}
**blind_spots:** 
  - No response clearly distinguishes 'confirmed serotypes' (DENV-1–4) from ongoing debates about what would count as formal recognition (e.g., ICTV taxonomy vs antigenic/neutralization-defined serotypes) and why DENV-5 remains 'putative' in many modern summaries.
  - None discuss the antibody-titer/time-interval dependence of ADE (cross-protection early after first infection vs higher risk later as neutralizing titers wane), which is central to why secondary infections are not uniformly severe.
  - None mention severe dengue in infants driven by waning maternal anti-DENV antibodies (a classic ADE context) as supporting evidence for the mechanism.
  - No response covers NS1’s role and endothelial glycocalyx/complement interactions (and anti-NS1 effects) as additional, evidence-backed contributors to vascular leak alongside ADE.
  - No response addresses viral and host heterogeneity that modulates severity (viral genotype/strain virulence, prior infection sequence, host genetics/HLA, age, pregnancy, comorbidities), which are important for a truth-seeking explanation beyond a single mechanism.

### RAW PANEL RESPONSES (что панель реально сказала):

**[openai/gpt-5.2]:**
The dengue virus has **4 confirmed serotypes**:

1. **DENV-1** (Dengue virus serotype 1)  
2. **DENV-2** (Dengue virus serotype 2)  
3. **DENV-3** (Dengue virus serotype 3)  
4. **DENV-4** (Dengue virus serotype 4)

(Some papers have discussed a possible “DENV-5,” but the widely accepted, confirmed human dengue serotypes remain **1–4**.)

## Why a second infection with a *different* serotype can be more severe
The main reason is **antibody-dependent enhancement (ADE)**, plus related immunologic effects:

- **After the first infection**, you develop antibodies that strongly neutralize that specific serotype and provide long-lasting protection against it.
- **On a later infection with a different serotype**, many existing antibodies can **bind** the new serotype but **don’t neutralize it well** (they’re “cross-reactive, sub-neutralizing” antibodies).
- These antibody–virus complexes can then attach to **Fcγ receptors** on immune cells such as **monocytes/macrophages and dendritic cells**, increasing viral entry into these cells and boosting viral replication.
- This can lead to **higher viremia** and an amplified inflammatory response (cytokines/chemokines, complement activation), contributing to **vascular leakage, bleeding tendency, and shock**—the hallmarks of severe dengue.

A secondary contributor often discussed is **cross-reactive T-cell responses** (“original antigenic sin”), where memory T cells generated from the first serotype respond to the second serotype in a way that may be **less effective at clearing infection** yet **more inflammatory**, further increasing the risk of severe disease.

**[google/gemini-3.1-pro-preview]:**
{
  "consensus": "There are four confirmed serotypes of the dengue virus, designated DENV-1, DENV-2, DENV-3, and DENV-4. A secondary infection with a different serotype typically causes more severe disease due to a mechanism known as Antibody-Dependent Enhancement (ADE). During ADE, sub-neutralizing antibodies generated from the first infection bind to the new serotype but fail to neutralize it. Instead, these antibody-virus complexes facilitate the entry of the virus into host immune cells (like macrophages and monocytes) via Fc receptors, leading to enhanced viral replication, a higher viral load, and an extreme, damaging immune response.",
  "contradictions": "There are no major contradictions among the responses. However, there is a minor divergence regarding a potential fifth serotype (DENV-5). Some models strictly state there are only four serotypes, while one model acknowledges the 2013 discovery of a sylvatic fifth serotype but notes it is not widely confirmed or clinically relevant for wider human populations.",
  "unique_insights": "One model introduces the concept of 'original antigenic sin' (or immune memory interference), explaining that cross-reactive, low-affinity memory T-cells from the first infection dominate the immune response during the second infection. This results in an inefficient viral clearance and massive inflammatory cytokine release, significantly contributing to vascular leakage and severe disease independent of ADE.",
  "blind_spots": "The models collectively focus heavily on ADE and immune response factors but omit discussion on the influence of viral genetics, specific strain virulence, and host genetic factors (such as HLA types), which also modulate the likelihood of developing severe dengue during a secondary infection.",
  "partial_coverage": "While all models cover the foundational concept of ADE, the exact molecular mechanisms, such as specifying the involvement of Fc-gamma receptors or detailing the specific cytokines contributing to the cytokine storm, are only partially covered across the individual responses.",
  "responses": [
    "The dengue virus has four confirmed serotypes, named DENV-1, DENV-2, DENV-3, and DENV-4. Getting infected with one serotype provides lifelong immunity against that specific serotype, but only temporary cross-immunity to the others. When a person is secondarily infected with a different serotype, they are at a higher risk of developing severe dengue (like Dengue Hemorrhagic Fever). This occurs largely because of Antibody-Dependent Enhancement (ADE). Antibodies from the first infection bind to the new, different virus serotype but cannot completely neutralize it. This antibody-virus complex binds to receptors (Fc receptors) on immune cells, giving the virus a 'trojan horse' entry into these cells. As a result, the virus replicates much more efficiently, leading to a massive viral load and a severe, damaging immune response known as a cytokine storm.",
    "There are 4 distinct but closely related serotypes of the virus that cause dengue (DENV-1, DENV-2, DENV-3, and DENV-4). Secondary infection with a heterologous (different) serotype is the greatest risk factor for severe dengue. This is driven by Antibody-Dependent Enhancement (ADE). During a first infection, the body produces neutralizing antibodies that clear the virus. Upon secondary infection with a different serotype, these pre-existing antibodies cross-react with the new virus but fail to neutralize it. Instead, they help the virus enter macrophages and monocytes through Fc-gamma receptors. This leads to increased viral production. Additionally, 'original antigenic sin' occurs, where cross-reactive memory T cells from the primary infection dominate the immune response, causing massive inflammatory cytokine release and vascular leakage.",
    "Dengue virus (DENV) consists of four confirmed serotypes: DENV-1, DENV-2, DENV-3, and DENV-4. A suggested fifth serotype (DENV-5) was reported in 2013 in a macaque epidemic in Malaysia, but it is not widely considered a confirmed human threat at this time. A second infection with a different serotype causes more severe illness due to Antibody-Dependent Enhancement (ADE). In ADE, antibodies from the primary infection bind to the second serotype but do not neutralize it. These antibody-virus complexes are then taken up by macrophages (a type of white blood cell). The virus takes over these cells to reproduce in large numbers, drastically increasing the v
…[обрезано, всего 4668 симв]

**[x-ai/grok-4.3]:**
{
  "consensus": "There are 4 confirmed dengue serotypes, named DENV-1, DENV-2, DENV-3, and DENV-4. Secondary infection with a different serotype often leads to more severe disease due to antibody-dependent enhancement (ADE), where pre-existing non-neutralizing antibodies facilitate greater viral entry into cells, triggering a cytokine storm.",
  "contradictions": [],
  "unique_insights": [
    "ADE process explained in detail leading to cytokine storm and hemorrhage/organ failure.",
    "Lifelong immunity only to the infecting serotype; short-term cross-protection.",
    "Risk of severe disease higher on second infection but can occur on first or later ones too."
  ],
  "blind_spots": [],
  "partial_coverage": false,
  "responses": [
    {
      "model": "NCBI Dengue Fever",
      "answer": "Dengue fever is caused by any of the 4 distinct serotypes (DENV-1 to DENV-4). Severe dengue is often associated with infection by a second dengue virus serotype and the patient's immune response."
    },
    {
      "model": "CDC Yellow Book",
      "answer": "Infection with any of the four DENV confers long-term immunity to that virus but only short-lived protection against the other three. The risk for severe dengue is greater during a second DENV infection."
    },
    {
      "model": "Gavi VaccinesWork",
      "answer": "The dengue virus has four serotypes (DENV1 to DENV4). Subsequent reinfections with a different serotype can be worse due to antibody-dependent enhancement (ADE), leading to higher viral replication and cytokine storm."
    },
    {
      "model": "Merck Manual",
      "answer": "There are 4 serotypes. More severe disease may result from antibody-dependent enhancement of infection, in which patients have a non-neutralizing antibody from a previous infection with one dengue serotype and then have another infection with a different dengue serotype."
    }
  ]
}

======================================================================
## C2_cn_open  (panel=[deepseek-v4-pro, glm-5.1, kimi-k2.6] | judge=qwen3-235b-a22b-2507)

### JUDGE-СИНТЕЗ (что судья извлёк):
**consensus:**   All retrieved sources confirm that the dengue virus has four confirmed serotypes: DENV-1, DENV-2, DENV-3, and DENV-4 (also referred to as dengue virus 1, 2, 3, and 4). They agree that infection with one serotype confers lasting immunity to that specific serotype but not to the others, and that secondary infection with a different serotype carries a greater risk of severe disease (such as dengue hemorrhagic fever or severe dengue).
**contradictions:** 
  There are no direct contradictions. A minor nuance exists between the NCBI Bookshelf, which states infection confers 'lifelong immunity to that serotype but not to others,' and the CDC Yellow Book, which states it confers 'long-term immunity to that virus but only short-lived protection against the other three dengue viruses.' This represents a difference in descriptive wording rather than a factual contradiction.
**unique_insights:** 
  The Merck Manual explicitly identifies the mechanism causing worse outcomes upon secondary infection with a different serotype as 'antibody-dependent enhancement (ADE) of infection,' explaining that non-neutralizing antibodies from a previous infection with one serotype enhance infection upon exposure to a different serotype. Additionally, the CDC Yellow Book and Merck Manual highlight that the dengue vaccine (Dengvaxia/CYD-TDV) can mimic this risk, increasing the chance of severe disease in individuals without prior dengue infection who are subsequently exposed, which parallels the ADE phenomenon.
**blind_spots:** 
  The retrieved snippets do not provide detailed molecular or cellular-level pathophysiology of antibody-dependent enhancement (e.g., specific Fc-gamma receptor interactions, complement activation pathways, or the precise cytokine cascade). They also do not mention or rule out the existence of any other potential or putative serotypes beyond the four confirmed ones.

### RAW PANEL RESPONSES (что панель реально сказала):

======================================================================
## C5_smartpanel_dumbjudge  (panel=[deepseek-v4-pro, glm-5.1, kimi-k2.6] | judge=qwen3-8b)

### JUDGE-СИНТЕЗ (что судья извлёк):
**consensus:**   - There are four confirmed serotypes: DENV-1, DENV-2, DENV-3, and DENV-4.
  - Secondary infection with a different serotype causes more severe disease due to Antibody-Dependent Enhancement (ADE).
**contradictions:** 
  - {"topic": "DENV-5 status", "stances": [{"model": "deepseek/deepseek-v4-pro", "stance": "Proposed but not confirmed as a sustained human serotype"}, {"model": "evidence", "stance": "No confirmed evidence of sustained human transmission for DENV-5"}]}
**unique_insights:** 
  - {"model": "moonshotai/kimi-k2.6", "insight": "CYD-TDV vaccine increases severe disease risk in seronegative recipients"}
  - {"model": "z-ai/glm-5.1", "insight": "ADE suppresses type I interferon signaling and promotes IL-10 production"}
**blind_spots:** 
  - Role of genetic polymorphisms in ADE susceptibility
  - Impact of climate change on serotype prevalence
  - Mechanistic differences between primary and secondary infections in children vs adults

### RAW PANEL RESPONSES (что панель реально сказала):

**[deepseek/deepseek-v4-pro]:**
The user is asking two clear, knowledge-based questions about the dengue virus. Unfortunately, the multi-model deliberation tool ("fusion") referenced in the instructions is not present in the available function list — only `openrouter_web_search` and `openrouter_web_fetch` are provided. Since I cannot invoke a tool that does not exist, I will answer directly from my own knowledge.

---

## 1. Confirmed Dengue Serotypes

There are **four** confirmed serotypes of the dengue virus:

- **DENV-1**
- **DENV-2**
- **DENV-3**
- **DENV-4**

These four belong to the genus *Flavivirus*, family *Flaviviridae*. A putative fifth serotype (DENV-5) was proposed in 2013 based on a sylvatic strain from Sarawak, Malaysia, but it is **not** widely accepted as a confirmed, sustained human serotype — human transmission has not been demonstrated beyond an isolated spillover event.

---

## 2. Why Secondary Heterotypic Infection Causes More Severe Disease

The primary mechanism is **Antibody-Dependent Enhancement (ADE)**:

### Step-by-step mechanism:

1. **Primary infection** → The immune system produces **type-specific neutralizing antibodies** against that serotype, plus broadly cross-reactive (but non-neutralizing or sub-neutralizing) antibodies against all four serotypes.

2. **Secondary infection with a different serotype** → The pre-existing cross-reactive antibodies bind to the new serotype's virions but **cannot neutralize** them (wrong epitope specificity, sub-neutralizing concentration, or low affinity).

3. **Enhanced entry** → These antibody–virus immune complexes are recognized by **Fcγ receptors (FcγR)** on the surface of monocytes, macrophages, and dendritic cells. The virus is internalized via Fc receptor-mediated endocytosis — effectively gaining access to cells it would otherwise infect less efficiently.

4. **Amplified replication** → Infected monocytes/macrophages become viral factories, leading to a **higher peak viremia** (viral load) than in primary infection.

5. **Dysregulated immune response**:
   - Massive activation of infected and bystander immune cells.
   - **Cytokine storm** — massive release of TNF-α, IL-6, IL-8, IL-10, and other pro-inflammatory mediators.
   - Activation of complement pathways.
   - **NS1 protein** (secreted by infected cells) directly damages endothelial glycocalyx and triggers complement activation, increasing vascular permeability.
   - T cell **"original antigenic sin"** — memory T cells from the primary infection respond to the new serotype with suboptimal affinity, contributing more to inflammation than to viral clearance.

6. **Clinical outcome** → Increased **vascular permeability** (plasma leakage), leading to dengue hemorrhagic fever (DHF) / severe dengue, which can progress to **dengue shock syndrome (DSS)**.

### Key additional risk factors:
- **Timing**: The highest risk window is when neutralizing antibodies have waned to sub-protective levels (roughly 6 months to 2–5 years post-primary infection).
- **Serotype pair**: Secondary infection with DENV-2 after primary DENV-1 is historically associated with the most severe outcomes.
- **Age & genetics**: Children and individuals with certain HLA alleles are at higher risk.

---

### Summary
- **4 confirmed serotypes**: DENV-1, DENV-2, DENV-3, DENV-4.
- **Severity in secondary heterotypic infection** is driven primarily by **Antibody-Dependent Enhancement (ADE)**, where non-neutralizing cross-reactive antibodies facilitate FcγR-mediated viral entry into myeloid cells, amplifying viral replication and triggering a pathological cytokine storm that increases vascular permeability, leading to severe dengue.

**[z-ai/glm-5.1]:**
## Dengue Virus Serotypes

The dengue virus has **4 confirmed serotypes**:

| Serotype | Common Name |
|----------|-------------|
| DENV-1 | Dengue virus type 1 |
| DENV-2 | Dengue virus type 2 |
| DENV-3 | Dengue virus type 3 |
| DENV-4 | Dengue virus type 4 |

These four serotypes share approximately **65% of their genomes**. Infection with any one serotype produces the same general range of clinical symptoms, and all four now co-circulate in tropical and subtropical regions worldwide.

---

## Why Secondary Infection with a Different Serotype Causes More Severe Disease

The principal mechanism is **Antibody-Dependent Enhancement (ADE)**, first proposed by Halstead in 1977. Here is how it works step by step:

### 1. Primary Infection → Type-Specific + Cross-Reactive Antibodies
- A primary DENV infection generates **lifelong, type-specific neutralizing antibodies** against the infecting serotype.
- It also generates **cross-reactive antibodies** that can bind to the other three serotypes, but these are **sub-neutralizing** (weak or non-neutralizing) against heterologous serotypes. Cross-neutralizing activity declines over weeks to months, while type-specific neutralization persists for decades.

### 2. Secondary Heterologous Infection → Immune Complexes Form
- When a different serotype infects, the pre-existing cross-reactive antibodies from the first infection bind to the new virus but **cannot fully neutralize it**.
- Instead, these antibody-virus **immune complexes** are recognized by **Fc gamma receptors (FcγR)** on the surface of monocytes, macrophages, and dendritic cells — the very cells that dengue virus naturally infects.

### 3. Extrinsic ADE — Enhanced Viral Entry
- The FcγR-mediated uptake **increases the number of target cells infected** and **accelerates the rate of viral internalization**, compared to infection without pre-existing antibodies. This is called **extrinsic ADE**.

### 4. Intrinsic ADE — Enhanced Viral Replication
- Once inside the cell via the FcγR pathway, the virus **suppresses the host's innate antiviral response**. Specifically, ADE entry:
  - **Inhibits type I interferon (IFN-α/β) signaling**, removing a key antiviral defense.
  - **Suppresses anti-inflammatory cytokines** like IL-12 and IFN-γ.
  - **Promotes IL-10 production**, which further dampens immune responses and favors a Th2-type environment.
- This **intrinsic ADE** results in **higher intracellular viral replication** per infected cell, and it is thought to contribute even more to the overall increase in viremia than extrinsic ADE alone.

### 5. Consequences — Immunopathology and Severe Disease
- The **dramatically increased viral load** triggers an intense inflammatory cascade: massive release of cytokines and chemokines (a "cytokine storm"), complement activation, and release of vasoactive mediators.
- This leads to the hallmarks of severe dengue: **increased vascular permeability**, **plasma leakage**, **thrombocytopenia**, **hemorrhage**, and potentially fatal **dengue shock syndrome (DSS)**.

### 6. "Original Antigenic Sin"
- The antibody response during secondary infection is biased toward the serotype of the *first* infection (a phenomenon called **original antigenic sin**). Rather than mounting a fresh, effective neutralizing response against the new serotype, the immune system preferentially recalls memory B cells from the primary infection — producing more cross-reactive, sub-neutralizing antibodies that further fuel ADE.

---

### Key Contributors to ADE Identified in Research

| Factor | Role in ADE |
|--------|------------|
| **Anti-prM antibodies** | Dominant cross-reactive response; poorly neutralizing even at high concentrations; potently enhance ADE because prM is only partially cleaved from mature virions |
| **Anti-E fusion-loop antibodies** | Target a highly conserved region of the envelope protein; cross-reactive but weakly neutralizing and strongly enhancing |
| **FcγR-bearing myeloid cells** | The portal of enhanced entry (monocytes, macrophages, dendritic cells) |

This is why dengue vaccine development has been so challenging: a vaccine must elicit **simultaneous, robust, neutralizing immunity against all four serotypes** — otherwise, sub-neutralizing immunity against any one serotype could paradoxically increase the risk of severe disease upon natural infection with that serotype.

**[moonshotai/kimi-k2.6]:**
```json
{
  "consensus": [
    "Dengue, an acute febrile illness, is caused by infection with any of four related single-stranded RNA viruses of the genus Flavivirus, dengue virus 1, 2, 3, or 4 (DENV1–4).",
    "There are four different but closely-related dengue virus types: dengue-1, dengue-2, dengue-3, and dengue-4.",
    "Infection with any of the four DENV confers long-term immunity to that virus but only short-lived protection against the other three dengue viruses.",
    "Subsequent reinfections with a different serotype can be so much worse, because of a process called antibody-dependent enhancement (ADE).",
    "This is when pre-existing antibodies to one serotype bind to the virus particles from the new serotype that is infecting us, but fail to neutralise them. Instead, this new virus-antibody complex is taken up by receptors that allow the virus to enter immune cells and replicate.",
    "The cytokine storm can provoke such a strong response by the immune system that rather than protecting us from the infection, it backfires, causing us to haemorrhage and our organs to fail."
  ],
  "contradictions": [],
  "unique_insights": [
    "Immunity to the other three serotypes can be as short as two months (GAVI).",
    "Microvascular permeability tends to escalate as viral titers decrease in severe dengue (NCBI).",
    "The dengue vaccine CYD-TDV is approved only for previously infected individuals and can increase risk of severe disease in seronegative recipients if subsequently infected (Merck Manual/CDC)."
  ],
  "blind_spots": [],
  "partial_coverage": [],
  "responses": [
    {
      "source": "CDC Yellow Book 2026 (NCBI Bookshelf)",
      "text": "Dengue, an acute febrile illness, is caused by infection with any of four related single-stranded RNA viruses of the genus Flavivirus, dengue virus 1, 2, 3, or 4 (DENV1–4). Infection with any of the four DENV confers long-term immunity to that virus but only short-lived protection against the other three dengue viruses. Severe dengue can be caused by any of the four DENV. The risk for severe dengue is greater during a second DENV infection, but severe dengue also can occur during the first or any subsequent infection."
    },
    {
      "source": "GAVI VaccinesWork",
      "text": "The dengue virus has four serotypes (denv1 to denv4) and we get infected by one of those serotypes at any one time. Although we develop lifelong immunity to that particular serotype, immunity to other three serotypes can be as short as two months, meaning the likelihood of a second infection – especially in a dengue outbreak – can be high. Subsequent reinfections with a different serotype can be so much worse, because of a process called antibody-dependent enhancement (ADE). This is when pre-existing antibodies to one serotype bind to the virus particles from the new serotype that is infecting us, but fail to neutralise them. Instead, this new virus-antibody complex is taken up by receptors that allow the virus to enter immune cells and replicate. This actually boosts the viral infection much higher than if the body didn't have pre-existing antibodies. In response, this infection spike triggers a flood of immune cells called cytokines, in an extreme immune response called a 'cytokine storm' – this response was also responsible for the most severe symptoms in COVID-19. The cytokine storm can provoke such a strong response by the immune system that rather than protecting us from the infection, it backfires, causing us to haemorrhage and our organs to fail."
    },
    {
      "source": "NCBI Bookshelf - Dengue Fever",
      "text": "Dengue fever is caused by any of the 4 distinct serotypes (DENV-1 to DENV-4) of single-stranded RNA viruses belonging to the genus Flavivirus. Infection by one serotype confers lifelong immunity to that serotype but not to others. Severe dengue fever, characterized by heightened microvascular permeability and shock syndrome, is often associated with infection by a second dengue virus serotype and the patient's immune response. However, severe cases of dengue fever can also arise from infection by a single serotype. Interestingly, microvascular permeability tends to escalate as viral titers decrease."
    },
    {
      "source": "Merck Manual Professional Edition",
      "text": "The causative agents, enveloped single-strand RNA viruses from the genus Flavivirus with 4 serotypes, are transmitted by the bite of Aedes mosquitoes. More severe disease may result
…[обрезано, всего 5009 симв]

======================================================================
## C5inv_dumbpanel_smartjudge  (panel=[qwen3-8b, gemma-3-12b-it, glm-4.7-flash] | judge=glm-5.1)

### JUDGE-СИНТЕЗ (что судья извлёк):
**consensus:**   - The dengue virus has four confirmed serotypes: DENV-1, DENV-2, DENV-3, and DENV-4.
  - Secondary infection with a different serotype causes more severe disease primarily via Antibody-Dependent Enhancement (ADE), where pre-existing non-neutralizing or sub-neutralizing antibodies bind the new serotype, facilitating viral entry into immune cells (monocytes/macrophages) via Fcγ receptors, increasing viral replication.
  - ADE triggers an exaggerated or dysregulated immune response, contributing to vascular leakage and severe dengue manifestations.
  - The risk and severity of ADE vary depending on the specific combination of serotypes involved in the primary and secondary infections.
**contradictions:** 
  - {"topic": "Number of confirmed serotypes", "stances": [{"model": "qwen/qwen3-8b", "stance": "Strictly four confirmed serotypes (DENV-1 to DENV-4)."}, {"model": "google/gemma-3-12b-it", "stance": "Four confirmed serotypes, but acknowledges the 'possibility of other, less common or unconfirmed serotypes'."}, {"model": "evidence", "stance": "A fifth serotype (DENV-5) was proposed in 2013 from a sylvatic cycle isolate in Malaysia, but it remains unconfirmed/unapproved by ICTV and has not caused widespread human outbreaks; four remains the accepted standard."}]}
  - {"topic": "Mechanisms of cytokine dysregulation in ADE", "stances": [{"model": "qwen/qwen3-8b", "stance": "ADE leads to a 'cytokine storm' with extreme immune response, implying predominantly overactive pro-inflammatory cytokines."}, {"model": "z-ai/glm-4.7-flash", "stance": "ADE triggers high levels of pro-inflammatory cytokines AND suppression of anti-inflammatory cytokines (or vice versa: elevated IL-10, an anti-inflammatory cytokine)."}, {"model": "evidence", "stance": "Intrinsic ADE involves complex immunomodulation: suppression of pro-inflammatory cytokines/Type I IFNs within infected monocytes, coupled with increased production of IL-10 and IL-6, which inhibit NO synthesis and Type I IFN pathways, promoting viral replication."}]}
**unique_insights:** 
  - {"model": "z-ai/glm-4.7-flash", "insight": "Intrinsic ADE mechanisms involve the virus-antibody complex using LILRB1 and SHP-1 to downregulate phagosome acidification and escape lysosomal degradation, allowing viral replication even after cell entry."}
  - {"model": "google/gemma-3-12b-it", "insight": "Molecular mimicry, where regions of different serotypes share structural similarities, could contribute to the severity of secondary infections beyond ADE."}
**blind_spots:** 
  - T-cell cross-reactivity and original antigenic sin: No model adequately addressed the significant role of cross-reactive CD8+ T cells, which have altered cytokine profiles (altered peptide ligand effect) and lower avidity for the new serotype, contributing to delayed viral clearance and immunopathology.
  - The DENV-5 serotype: While one model vaguely alluded to unconfirmed serotypes, no model explicitly discussed the proposed fifth serotype (DENV-5), isolated in 2007/2013 from a sylvatic cycle, and its implications for current tetravalent vaccines.
  - Infant severe dengue: Severe dengue can also occur in infants experiencing primary infection (6-12 months) due to waning maternal antibodies entering the ADE window, which contradicts the models' implicit framing that severe disease strictly requires prior natural infection.
  - Innate immune suppression during intrinsic ADE: The suppression of Type I interferon and nitric oxide radical pathways within infected monocytes, which directly facilitates viral replication, was largely missed or oversimplified as just a 'cytokine storm'.

### RAW PANEL RESPONSES (что панель реально сказала):

**[qwen/qwen3-8b]:**
{
  "consensus": "The dengue virus has four confirmed serotypes: DENV-1, DENV-2, DENV-3, and DENV-4. Infection with one serotype provides lifelong immunity to that specific serotype but not to others.",
  "contradictions": [],
  "unique_insights": [
    "Secondary infections with a different serotype trigger antibody-dependent enhancement (ADE), where pre-existing antibodies bind to the new serotype but fail to neutralize it, facilitating viral entry into immune cells and increasing replication.",
    "This leads to a cytokine storm, an extreme immune response causing severe symptoms like hemorrhage and organ failure, which is more pronounced in secondary infections."
  ],
  "blind_spots": [
    "The exact thresholds for ADE occurrence and its variability across serotype combinations are not fully detailed.",
    "Mechanistic nuances of cytokine-specific interactions during ADE remain underexplored in the provided sources."
  ],
  "partial_coverage": [
    "Vaccine-related risks (e.g., Dengvaxia) are mentioned but not central to the core question about serotypes and disease severity.",
    "The role of viral load dynamics and host genetic factors in modulating disease severity is not explicitly addressed."
  ],
  "responses": [
    "The dengue virus has four serotypes (DENV-1 to DENV-4). Secondary infections with a different serotype cause more severe disease due to antibody-dependent enhancement (ADE), where prior antibodies facilitate viral entry into immune cells, leading to heightened replication and cytokine storms.",
    "Dengue is caused by four serotypes (DENV-1–4). Secondary infections with a different serotype can cause more severe disease via ADE, where non-neutralizing antibodies enhance viral infection and trigger excessive immune responses.",
    "Dengue is caused by four serotypes (DENV1–4). Severe dengue is more likely during secondary infections due to ADE, where prior antibodies bind the new serotype, enabling viral entry and exacerbating immune responses.",
    "Dengue has four serotypes (dengue-1, dengue-2, dengue-3, dengue-4). Secondary infections with a different serotype are deadlier due to ADE, where antibodies from the first infection bind the new virus, leading to increased replication and cytokine storms.",
    "The dengue virus has four serotypes (DENV1–4). Secondary infections with a different serotype cause more severe disease through ADE, where pre-existing antibodies enhance viral entry and trigger excessive immune responses."
  ]
}

**[google/gemma-3-12b-it]:**
```json
{
  "consensus": "Dengue virus has four confirmed serotypes: DENV-1, DENV-2, DENV-3, and DENV-4. Secondary infection with a different serotype leads to more severe disease due to antibody-dependent enhancement (ADE).",
  "contradictions": [],
  "unique_insights": [
    "While initially, it was believed that previous infection conferred lifelong immunity to all dengue serotypes, it's now understood that this isn't the case, and subsequent infections with different serotypes pose a higher risk.",
    "The severity of secondary dengue infections varies depending on the serotype involved and individual factors like genetic predisposition and prior exposure.",
    "Molecular mimicry, where regions of different serotypes share structural similarities, could also play a role in the severity of secondary infections."
  ],
  "blind_spots": [
    "The exact mechanisms of ADE are still being investigated and not fully understood.",
    "The role of innate immune responses in secondary dengue infections is not fully elucidated.",
    "Predictive markers for severe dengue following secondary infection remain elusive, hindering effective clinical management."
  ],
  "partial_coverage": [
    "Some sources suggest the possibility of other, less common or unconfirmed serotypes, but these are not widely accepted.",
    "The discussion on the reasons for increased severity primarily focuses on antibody-dependent enhancement (ADE), with less emphasis on other potential contributing factors."
  ],
  "responses": [
    {
      "panel": "GPT-3.5",
      "answer": "Dengue virus has four confirmed serotypes: DENV-1, DENV-2, DENV-3, and DENV-4. Secondary infection with a different serotype causes more severe disease due to a phenomenon called antibody-dependent enhancement (ADE). When a person is infected with one serotype of dengue, their immune system produces antibodies. These antibodies are typically effective at neutralizing that specific serotype. However, if a person is subsequently infected with a different serotype, the antibodies produced during the first infection may bind to the new serotype but fail to neutralize it effectively. Instead, these antibodies facilitate the entry of the virus into immune cells, increasing viral replication and leading to more severe disease. This is because the antibody complexes form immune complexes that are then taken up by Fc receptors on monocytes/macrophages, leading to increased viral replication within these cells. The specific serotype combination also influences the severity – some serotype pairs are associated with higher risk of severe disease."
    },
    {
      "panel": "Claude-3-Sonnet",
      "answer": "There are four confirmed serotypes of the dengue virus: DENV-1, DENV-2, DENV-3, and DENV-4. Secondary infection with a different serotype (compared to the initial infection) generally results in more severe disease, and this is primarily due to a process called antibody-dependent enhancement (ADE). Here's a breakdown:\n\n*   **The Initial Infection:** When you're first infected with a dengue serotype, your body produces antibodies specific to that serotype. These antibodies are designed to neutralize the virus and prevent further infection.\n*   **Secondary Infection with a Different Serotype:** If you're later infected with a *different* serotype, the antibodies you produced during the first infection don't effectively neutralize the new virus. Instead, these antibodies bind to the new serotype and actually *enhance* its entry into immune cells (like macrophages).  This increased viral entry leads to greater viral replication and a more severe immune response, resulting in more severe dengue disease.\n*   **Why this happens (ADE):**  The antibody-virus complexes created by this mismatched antibody binding are taken up by immune cells via Fc receptors, leading to increased viral replication *within* the cells and a stronger inflammatory response.\n\nIt's important to note that the risk and severity of secondary dengue infections can vary depending on which serotypes are involved."
    },
    {
      "panel": "Gemini-1.5-Pro",
      "answer": "The dengue virus has four confirmed serotypes: DENV-1, DENV-2, DENV-3, and DENV-4. Secondary infection with a different serotype causes more severe disease than the first infection primarily due to a phenomenon called antibody-dependent enhancement (ADE).\n\nHere's a more detailed explanation:\n\n*   **Initial Infection and Antibody Produ
…[обрезано, всего 5654 симв]

**[z-ai/glm-4.7-flash]:**
Based on the search results, here's the information about dengue virus serotypes and the mechanism of severe secondary infection:

## Dengue Virus Serotypes

The dengue virus has **4 confirmed serotypes**:

1. **DENV-1** (Dengue virus type 1)
2. **DENV-2** (Dengue virus type 2)
3. **DENV-3** (Dengue virus type 3)
4. **DENV-4** (Dengue virus type 4)

Each serotype is genetically distinct but related, with approximately 30-35% sequence variation between them. Each serotype confers lifelong immunity against itself, but only provides limited or temporary protection against the other serotypes.

## Why Secondary Infection with a Different Serotype Causes More Severe Disease

The mechanism is known as **Antibody-Dependent Enhancement (ADE)**. Here's how it works:

### Primary Infection
- After the first dengue infection, the body produces antibodies specific to that serotype
- These antibodies are highly effective at neutralizing that particular serotype
- The infection typically results in a self-limiting, often mild illness

### Secondary Infection with a Different Serotype
1. **Cross-reactive but non-neutralizing antibodies**: The antibodies from the first infection can bind to the new serotype, but they are often insufficient to neutralize it completely, especially at sub-neutralizing concentrations.

2. **Fcγ receptor-mediated entry**: The virus-antibody immune complexes are recognized by Fcγ receptors (specifically FcγRIIa and FcγRIIIa) on immune cells like monocytes, macrophages, and dendritic cells.

3. **Enhanced viral replication**: These complexes facilitate viral entry into immune cells, where the virus can replicate more efficiently than it would in the absence of antibodies.

4. **Exaggerated immune response**: The enhanced viral replication triggers an overactive immune response with high levels of pro-inflammatory cytokines (including IL-6, IL-10, and others) and suppression of anti-inflammatory cytokines.

5. **Vascular leakage**: This immune dysregulation leads to increased vascular permeability, causing plasma leakage, thrombocytopenia, hemorrhagic manifestations, and potentially hypovolemic shock (dengue hemorrhagic fever/dengue shock syndrome).

### Key Points
- Only about 2-4% of secondary heterotypic dengue infections develop severe disease
- The risk is highest when antibody levels are in a specific "enhancement window" (neither too low nor too high)
- The severity is associated with elevated levels of Fc glycoforms that bind more strongly to activating Fcγ receptors

This phenomenon explains why secondary dengue infections are the greatest risk factor for severe dengue disease, despite the body having some level of immunity from the first infection.

======================================================================
## C6_echo  (panel=[qwen3-235b-a22b-2507, qwen3-235b-a22b-2507, qwen3-235b-a22b-2507] | judge=qwen3-235b-a22b-2507)

### JUDGE-СИНТЕЗ (что судья извлёк):
**consensus:**   - The dengue virus has four confirmed serotypes: DENV-1, DENV-2, DENV-3, and DENV-4.
  - Secondary infection with a different serotype increases the risk of severe dengue, though severe disease can also occur in primary infections.
  - Antibody-dependent enhancement (ADE) is the primary mechanism explaining increased severity in secondary heterologous infections, where non-neutralizing antibodies from the primary infection facilitate increased viral entry into Fc receptor-bearing cells, leading to higher viremia and immunopathology.
**contradictions:** 
  - {"topic": "ADE as universally accepted mechanism", "stances": [{"model": "qwen/qwen3-235b-a22b-2507", "stance": "ADE is consistently named and described as the key mechanism for increased severity in secondary infection."}, {"model": "evidence", "stance": "While ADE is dominant in textbooks, recent studies highlight its limitations: some patients with severe primary dengue exhibit high antibody titers suggesting prior unrecognized infection, and infant models show ADE occurs only within a narrow window of waning maternal antibodies. Additionally, T-cell immunopathology and viral genetic factors contribute significantly, implying ADE is necessary but not sufficient alone."}]}
**unique_insights:** 
  - {"model": "qwen/qwen3-235b-a22b-2507", "insight": "The PLOS Neglected Tropical Diseases study in Nicaragua demonstrates that DENV-3 causes significant severity in both primary and secondary infections, challenging the assumption that severe disease is predominantly secondary, and highlighting serotype-specific pathogenic differences."}
**blind_spots:** 
  - None of the models discuss the role of viral genetic diversity (intra-serotype genotypes) in modulating virulence and disease outcomes.
  - No mention of the impact of pre-existing flavivirus immunity (e.g., Zika, yellow fever) on dengue severity via original antigenic sin or cross-protection.
  - Limited discussion on sex-based differences in immune response and clinical outcomes in dengue.
  - The socioeconomic and healthcare system burdens of dengue in endemic countries, including costs of hospitalization and vector control, are overlooked.
  - No model references the latest dengue vaccine developments post-2023, such as the rollout of Qdenga in Brazil or phase 3 results for TV003.

### RAW PANEL RESPONSES (что панель реально сказала):
_(responses отсутствуют для этого вопроса/конфига)_

======================================================================
## C3_cn_small  (panel=[qwen3.6-27b, glm-4.7-flash, qwen3-32b] | judge=qwen3-32b)

### JUDGE-СИНТЕЗ (что судья извлёк):
**consensus:**   - There are four confirmed dengue virus serotypes (DENV-1, DENV-2, DENV-3, DENV-4).
  - Secondary infection with a different serotype causes more severe disease via antibody-dependent enhancement (ADE).
**contradictions:** 
  _(пусто)_
**unique_insights:** 
  - {"model": "z-ai/glm-4.7-flash", "insight": "Quantified ADE progression to severe disease (<5%) and explicitly linked cytokine suppression (IL-12, IFN-γ) to immune dysfunction."}
  - {"model": "qwen/qwen3-32b", "insight": "Highlighted 'original antigenic sin' as a factor in antibody ineffectiveness during secondary infections."}
**blind_spots:** 
  - Role of T-cell-mediated immune responses in secondary dengue pathogenesis (mechanisms like CD4+ T-cell cross-reactivity and cytokine imbalance).
  - Population-level immune dynamics (e.g., seroprevalence trends and age-specific risk patterns).

### RAW PANEL RESPONSES (что панель реально сказала):

**[qwen/qwen3.6-27b]:**
There are **4** confirmed serotypes of the dengue virus.

### List of Dengue Serotypes
1.  **DENV-1** (Dengue virus type 1)
2.  **DENV-2** (Dengue virus type 2)
3.  **DENV-3** (Dengue virus type 3)
4.  **DENV-4** (Dengue virus type 4)

### Why Secondary Infection Causes More Severe Disease
The increased severity of the second infection—specifically when caused by a *different* serotype (heterotypic infection)—is largely explained by a phenomenon known as **Antibody-Dependent Enhancement (ADE)**.

Here is the mechanism of why this occurs:

1.  **Incomplete Protection:** A primary infection with one serotype (e.g., DENV-1) produces antibodies that protect you from getting sick from that specific serotype again. However, these same antibodies do not provide full protection against other serotypes (DENV-2, 3, or 4).
2.  **The "Trojan Horse" Effect (ADE):** When the body is infected by a different serotype, the pre-existing antibodies from the first infection bind to the new virus. Because they are not perfectly matched, they cannot neutralize the virus. Instead, the virus becomes "tagged" by these antibodies.
3.  **Cellular Entry:** Immune cells, such as macrophages, have receptors (Fc receptors) designed to eat antibody-tagged debris. These cells grab the tagged virus to destroy it, but dengue uses this to its advantage to enter and replicate inside the macrophages in massive numbers.
4.  **Cytokine Storm and Leakage:** Because the virus replicates so rapidly inside a large population of immune cells, it triggers an overwhelming immune response known as a "cytokine storm." This massive release of inflammatory chemicals damages the lining of blood vessels, causing them to become leaky (vascular permeability). This leakage of plasma fluid is the hallmark of **Dengue Hemorrhagic Fever (DHF)** and **Dengue Shock Syndrome (DSS)**, which are life-threatening complications.

**[z-ai/glm-4.7-flash]:**
Based on the search results, here are the answers to your questions:

## Number of Dengue Virus Serotypes

There are **4 confirmed serotypes** of the dengue virus:

1. **DENV-1** (Dengue virus 1)
2. **DENV-2** (Dengue virus 2)
3. **DENV-3** (Dengue virus 3)
4. **DENV-4** (Dengue virus 4)

Each serotype has distinct antigenicity and phylogeny, and infection with one serotype confers lifelong immunity to that specific serotype but only short-lived protection against the other three.

## Why Secondary Infection with a Different Serotype Causes More Severe Disease

The primary mechanism is **antibody-dependent enhancement (ADE)**, which occurs through several interconnected processes:

### 1. Cross-Reactive Non-Neutralizing Antibodies
- After a primary infection, the immune system produces antibodies that are specific to the infecting serotype but also cross-react with other serotypes
- These cross-reactive antibodies are often **non-neutralizing** or only **partially neutralizing** (approximately 30-35% sequence variation between serotypes prevents complete neutralization)

### 2. Fcγ Receptor-Mediated Entry
- During a secondary infection with a different serotype, pre-existing cross-reactive antibodies bind to the new virus but fail to neutralize it effectively
- The antibody-virus immune complexes are taken up by **Fcγ receptors (FcγR)** on monocytes, macrophages, and dendritic cells
- This facilitates viral entry into these immune cells, which are major sites of DENV replication

### 3. Enhanced Viral Replication
- Through ADE, the virus replicates more efficiently in FcγR-bearing cells
- This leads to **higher viremia** and increased viral load compared to primary infection

### 4. Dysregulated Immune Response
- ADE triggers an exaggerated inflammatory response
- There's suppression of antiviral cytokines (IL-12, IFN-γ, nitric oxide) while pro-inflammatory cytokines (IL-6, IL-10) are elevated
- This creates a Th2-skewed immune response that favors viral persistence

### 5. Pathological Consequences
- The enhanced viral replication and immune dysregulation cause:
  - **Vascular hyperpermeability** (plasma leakage)
  - **Thrombocytopenia** (low platelet count)
  - **Hemorrhagic manifestations**
  - Potentially **dengue hemorrhagic fever (DHF)** and **dengue shock syndrome (DSS)**

### 6. Original Antigenic Sin
- The immune response during secondary infection is skewed toward the first serotype's antigens
- This "original antigenic sin" means the body produces antibodies that are less effective against the new serotype

This ADE mechanism explains why secondary infections with a different dengue serotype carry a significantly higher risk of severe disease compared to primary infections, though it's worth noting that only a minority (<5%) of individuals with ADE actually progress to severe dengue.

**[qwen/qwen3-32b]:**
ool_call>{
  "consensus": 3,
  "contradictions": [],
  "unique_insights": [],
  "blind_spots": [
    "The provided documents confirm the existence of four dengue virus serotypes (DENV-1, DENV-2, DENV-3, DENV-4) but do not explicitly explain the immunological mechanism behind severe secondary infections. The genetic diversity and lineage circulation are discussed, but the specific reason (antibody-dependent enhancement, ADE) is not mentioned in the search results."
  ],
  "partial_coverage": [],
  "responses": [
    "The dengue virus has four confirmed serotypes: DENV-1, DENV-2, DENV-3, and DENV-4. Multiple recent outbreaks in 2023-2024 across Brazil, Colombia, Nepal, Taiwan, and Italy demonstrate the global circulation of all four serotypes, with specific emphasis on DENV-3 re-emergence and lineage diversification.",
    "Secondary infection with a different dengue serotype increases severe disease risk due to immune mechanisms involving antibody-dependent enhancement (ADE). While not explicitly detailed in the provided texts, prior immunological knowledge establishes that pre-existing antibodies from a first infection bind but fail to neutralize a heterologous serotype, facilitating macrophage entry and higher viral loads, which correlates with severe dengue manifestations like hemorrhage or shock.",
    "The 2023-2024 outbreak data highlights co-circulating serotypes (DENV-1, DENV-2, DENV-3) and reintroduction of DENV-3 after >15 years in Brazil, suggesting 'serotype immunity gaps' in populations naive to certain strains. Documented case data from Colombia and Nepal associates DENV-2 dominance with large outbreaks, but does not mechanistically link secondary infections to severity within the provided content."
  ]
}